Sisneo Bioscience is a biotechnology company focused on aesthetics and electromedicine. With a complete electromedicine, engineering and research team, develop the most advance devices in the market.
Besides the R+D Department in Moncada, Valencia, Sisneo have a development team inside the Nanofotonic Institute NTC in Valencia Polytechnical University.
Sisneo are currently developing a new cancer treatment system using non-contact electroporation technology.
Encapsulation systems for active ingredients not only preserve them from oxidation or interactions that could destabilize formulas but also dramatically increase the absorption rate into the skin.
Liposomes, the earliest encapsulation technology, and newer alternatives like nanosomes, niosomes, transferosomes, and exosomes, all have limitations. The amount of active ingredient each can carry is very small, and adding a high concentration of encapsulated ingredients often destabilises the formula. As a result, only small amounts are used, which, despite the higher effectiveness of the active ingredient, still yield significant results.
Sisneo Bioscience have developed a system that enables the encapsulation of active ingredients immediately before application, resulting in a highly flexible encapsulation process that allows for exceptional transdermal and transcutaneous penetration. This new encapsulation system is called genosomes.
This groundbreaking new device is called TDX20 (Transdermal Delivery x 20), as it multiplies the effectiveness by 20 times and enables active ingredients to be encapsulated in genosomes.
The TDX20 system enables the creation of the most potent cosmetic serum in the world, something impossible to formulate in a laboratory and maintain stability throughout the commercial distribution chain. This makes it a unique system globally.